Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
Protective Immunity and New Vaccines for Lyme Disease.
Клиническое исследованиеСтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gomes-Solecki Maria, Arnaboldi Paul M, Backenson P Bryon, Benach Jorge L, Cooper Christopher L, Dattwyler Raymond J, Diuk-Wasser Maria, Fikrig Erol, Hovius J W, Laegreid Will, Lundberg Urban, Marconi Richard T, Marques Adriana R, Molloy Philip, Narasimhan Sukanya, Pal Utpal, Pedra Joao H F, Plotkin Stanley, Rock Daniel L, Rosa Patricia, Telford Sam R, Tsao Jean, Yang X Frank, Schutzer Steven E
Аннотация
Lyme disease, caused by some Borrelia burgdorferi sensu lato, is the most common tick-borne illness in the Northern Hemisphere and the number of cases, and geographic spread, continue to grow. Previously identified B. burgdorferi proteins, lipid immunogens, and live mutants lead the design of canonical vaccines aimed at disrupting infection in the host. Discovery of the mechanism of action of the first vaccine catalyzed the development of new strategies to control Lyme disease that bypassed direct vaccination of the human host. Thus, novel prevention concepts center on proteins produced by B. burgdorferi during tick transit and on tick proteins that mediate feeding and pathogen transmission. A burgeoning area of research is tick immunity as it can unlock mechanistic pathways that could be targeted for disruption. Studies that shed light on the mammalian immune pathways engaged during tick-transmitted B. burgdorferi infection would further development of vaccination strategies against Lyme disease.